Examkin

Question

Difficulty: HardEnd-of-Life and Palliative Care

Evaluate the following end-of-life patient presentations and pair them with the optimal pharmacological intervention.

  • An individual receiving hospice care for metastatic breast carcinoma experiences sharp, predictable exacerbations of pain localized to the chest wall that occur exclusively during daily wound care.Prescribe an immediate-release, short-acting opioid to be administered 30 to 45 minutes before the inciting event.
  • A patient with advanced prostatic malignancy and concomitant anuric chronic kidney disease requires initiation of strong analgesia for severe, constant back pain.Initiate analgesia with an agent that lacks renally cleared active neurotoxic metabolites, such as fentanyl or methadone.
  • A comatose patient in the final hours of life following a massive ischemic stroke develops noisy, gurgling respirations that are highly distressing to the family members at the bedside.Administer an anticholinergic medication, such as sublingual hyoscyamine or subcutaneous glycopyrrolate.
  • A patient with end-stage idiopathic pulmonary fibrosis on maximal oxygen therapy continues to experience severe, intractable shortness of breath while completely at rest.Initiate low-dose systemic morphine to centrally decrease the sensation of breathlessness.

Answer

The presentations map to their interventions as follows: incident wound care pain requires a preemptive short-acting opioid; severe pain with anuric renal failure requires an opioid lacking neurotoxic metabolites (e.g., fentanyl); terminal airway secretions require an anticholinergic agent; and refractory resting dyspnea requires low-dose systemic opioids.
Each pairing represents the guideline-directed standard of care for complex palliative symptoms. Preemptive short-acting opioids effectively mitigate incident pain. Fentanyl and methadone are safe in renal failure because they lack renally cleared neurotoxic metabolites, unlike morphine. Anticholinergics such as glycopyrrolate dry up terminal airway secretions without crossing the blood-brain barrier. Systemic opioids are the cornerstone of treatment for refractory dyspnea, altering the central perception of breathlessness.

Step-by-Step Solution

1
Analyze each clinical presentation to identify the primary palliative symptom or physiological challenge.
Identified: predictable incident pain, pain in the setting of severe renal impairment, terminal airway secretions, and refractory dyspnea.
Accurate identification of the underlying symptom etiology is required to select the correct targeted therapy.
2
Evaluate the pharmacological options against patient-specific comorbidities and symptom profiles.
Morphine must be avoided in renal failure; opioids are indicated for dyspnea; anticholinergics dry secretions; and short-acting opioids address predictably timed breakthrough pain.
Palliative pharmacology requires careful matching of drug pharmacokinetics (e.g., renal clearance, onset of action) to the clinical context.
3
Pair each scenario with the corresponding optimal intervention.
The final matched pairs resolve all clinical scenarios safely and effectively according to established palliative care guidelines.
This confirms the synthesis of clinical assessment and pharmacological knowledge.

Key Concept

Effective palliative symptom management requires tailoring pharmacological interventions to the specific symptom (e.g., opioids for dyspnea, anticholinergics for secretions) while avoiding agents with toxic pharmacokinetic profiles in the presence of organ failure (e.g., avoiding morphine in end-stage renal disease).
Rate this question

Topics

End-of-Life and Palliative Care

More questions from this topic